$GHSI
Guardion Health Sciences Inc Stock $ghsi

$ghsi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223012449 Filed on April 17, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q3
Revenue	$3.186M	$2.726M	$2.664M
YoY Change	33.59%	3.76%	-15.41%
Cost Of Revenue	$1.850M	$1.790M	$1.575M
YoY Change	43.65%	14.47%	-10.52%
Gross Profit	$1.335M	$936.2K	$1.088M
YoY Change	21.78%	-11.98%	-21.6%
Gross Profit Margin	41.92%	34.34%	40.85%
Selling, General & Admin	$2.737M	$2.188M	$2.758M
YoY Change	-25.75%	-41.27%	-32.32%
% of Gross Profit	204.94%	233.75%	253.46%
Research & Development	$62.73K	$31.38K	$60.20K
YoY Change	837.73%	191.64%	270.94%
% of Gross Profit	4.7%	3.35%	5.53%
Depreciation & Amortization	$4.790K	$302.4K	$14.72K
YoY Change	-98.49%	-7.0%	-95.36%
% of Gross Profit	0.36%	32.3%	1.35%
Operating Expenses	$2.799M	$2.220M	$2.828M
YoY Change	-24.18%	-40.6%	-30.89%
Operating Profit	-$1.464M	-$1.284M	-$1.739M
YoY Change	-43.6%	-51.99%	-35.66%
Interest Expense	$1.997M	$2.444M	$43.28K
YoY Change	127919.23%	284075.58%
% of Operating Profit
Other Income/Expense, Net	$1.997M	$2.346M	$916.5K
YoY Change	-174.49%
Pretax Income	$533.1K	-$8.906M	-$1.696M
YoY Change	-120.36%	-38.67%	-43.74%
Income Tax
% Of Pretax Income
Net Earnings	$533.1K	-$9.847M	-$1.696M
YoY Change	-120.36%	-32.18%	-43.74%
Net Earnings / Revenue	16.73%	-361.18%	-63.68%
Basic Earnings Per Share	$0.42		-$0.03
Diluted Earnings Per Share	$0.42	-$7.99	-$27.53K
COMMON SHARES
Basic Shares Outstanding	1.267M shares	61.60M shares	61.60M shares
Diluted Shares Outstanding	1.267M shares		1.232M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.775M	$15.91M	$12.95M
YoY Change	-47.86%	74.99%	22.61%
Cash & Equivalents	$8.775M	$10.66M	$12.95M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$590.7K	$687.9K	$1.038M
YoY Change	-17.69%	-42.69%	-16.71%
Inventory	$3.061M	$3.119M	$1.953M
Prepaid Expenses			$1.038M
Receivables	$1.947M	$1.924M	$1.874M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.37M	$21.64M	$17.81M
YoY Change	-30.12%	79.28%	19.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.73K	$48.87K	$53.76K
YoY Change	-51.47%	-56.12%	-82.01%
Goodwill
YoY Change
Intangibles		$0.00	$10.36M
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$45.73K	$48.87K	$10.42M
YoY Change	-99.59%	-99.57%	-56.13%
TOTAL ASSETS
Total Short-Term Assets	$14.37M	$21.64M	$17.81M
Total Long-Term Assets	$45.73K	$48.87K	$10.42M
Total Assets	$14.42M	$21.69M	$28.23M
YoY Change	-54.4%	-7.56%	-26.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$888.6K	$1.518M	$1.041M
YoY Change	-22.49%	528.99%	-12.03%
Accrued Expenses	$508.7K	$558.3K	$683.2K
YoY Change	-25.19%	-37.65%	-13.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.178M	$4.012M	$1.733M
YoY Change	19.25%	246.11%	-12.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.759M	$4.507M	$0.00
YoY Change		118183.46%
Total Long-Term Liabilities	$3.759M	$4.507M	$0.00
YoY Change		118183.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.178M	$4.012M	$1.733M
Total Long-Term Liabilities	$3.759M	$4.507M	$0.00
Total Liabilities	$5.937M	$8.518M	$1.733M
YoY Change	225.07%	632.52%	-12.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.19M	-$93.72M	-$84.82M
YoY Change	10.81%	18.94%
Common Stock	$1.267K	$1.267K	$61.60K
YoY Change		-94.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.482M	$7.918M	$26.49M
YoY Change
Total Liabilities & Shareholders Equity	$14.42M	$21.69M	$28.23M
YoY Change	-54.4%	-7.56%	-26.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	$533.1K	-$9.847M	-$1.696M
YoY Change	-120.36%	-32.18%	-43.74%
Depreciation, Depletion And Amortization	$4.790K	$302.4K	$14.72K
YoY Change	-98.49%	-7.0%	-95.36%
Cash From Operating Activities	-$1.879M	-$1.364M	-$1.282M
YoY Change	-15.6%	-12.92%	-28.48%
INVESTING ACTIVITIES
Capital Expenditures	$1.654K	$0.00	-$3.170K
YoY Change	-168.92%	-100.0%	-95.81%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$10.01M
YoY Change	-100.0%	-100.0%	-14381.09%
Cash From Investing Activities	-$1.654K	$0.00	$10.00M
YoY Change	-99.98%	-100.0%	-6964.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$5.250M	4.323M	0.000
YoY Change	-152.66%
NET CHANGE
Cash From Operating Activities	-$1.879M	-1.364M	-1.282M
Cash From Investing Activities	-$1.654K	0.000	10.00M
Cash From Financing Activities	-$5.250M	4.323M	0.000
Net Change In Cash	-$7.131M	2.959M	8.721M
YoY Change	-1065.52%	458.32%	-549.89%
FREE CASH FLOW
Cash From Operating Activities	-$1.879M	-$1.364M	-$1.282M
Capital Expenditures	$1.654K	$0.00	-$3.170K
Free Cash Flow	-$1.881M	-$1.364M	-$1.279M
YoY Change	-15.43%	-13.04%	-25.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001642375
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent		usd
CY2021Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	GHSI	Intangible Asset Impairments IntangibleAssetImpairments		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	GHSI	Shares Issued In Connection To Reverse Split Due To Rounding SharesIssuedInConnectionToReverseSplitDueToRounding		usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Increase Decrease In Due To Officers And Stockholders IncreaseDecreaseInDueToOfficersAndStockholders		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	GHSI	Adjust Warrant Liability AdjustWarrantLiability		usd
CY2021	GHSI	Issuance Of Warrant Liability IssuanceOfWarrantLiability		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2022Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross		usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross		usd
CY2022Q4	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2020Q4	us-gaap	Goodwill Goodwill		usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	GHSI	Effective Income Tax Rate Reconciliation Nondeductible Goodwill Impairment Charge EffectiveIncomeTaxRateReconciliationNondeductibleGoodwillImpairmentCharge		pure
CY2021	GHSI	Effective Income Tax Rate Reconciliation Nondeductible Goodwill Impairment Charge EffectiveIncomeTaxRateReconciliationNondeductibleGoodwillImpairmentCharge		pure
CY2021Q4	GHSI	Deferred Tax Liabilities Unrealized Gains Losses DeferredTaxLiabilitiesUnrealizedGainsLosses		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38861
CY2022	dei	Entity Registrant Name EntityRegistrantName	GUARDION HEALTH SCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4428421
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2925 Richmond Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77098
CY2022	dei	City Area Code CityAreaCode	800
CY2022	dei	Local Phone Number LocalPhoneNumber	873-5141
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	GHSI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	9200000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1267340	shares
CY2022	dei	Auditor Firm AuditorFirmId	572
CY2022	dei	Auditor Name AuditorName	Weinberg & Company, P.A
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10655490	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4093927	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5250000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	4995623	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1924353	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1411567	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	367691	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687933	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1200376	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21637197	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	12069184	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48871	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111378	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11255833	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24257	usd
CY2022Q4	us-gaap	Assets Assets	21686068	usd
CY2021Q4	us-gaap	Assets Assets	23460652	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1518052	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	241347	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	558287	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	895477	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3807	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22221	usd
CY2022Q4	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent	1931400	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4011546	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1159045	usd
CY2022Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	4506600	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3807	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8518146	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1162852	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5250000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1267340	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1267340	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488539	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	488539	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1267	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	489	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101640955	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101099383	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93724300	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78802072	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22297800	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21686068	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23460652	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11049772	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7233118	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6529385	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4122684	usd
CY2022	us-gaap	Gross Profit GrossProfit	4520387	usd
CY2021	us-gaap	Gross Profit GrossProfit	3110434	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193800	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64358	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2069660	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2324569	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9577987	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11204885	usd
CY2022	GHSI	Intangible Asset Impairments IntangibleAssetImpairments	10065833	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2103680	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-106477	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-9448	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-160137	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21940985	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	27857240	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17420598	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-24746806	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2345800	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	152570	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	1797	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2498370	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1797	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14922228	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24745009	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	941585	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15863813	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24745009	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.15
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-52.23
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1121000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	473772	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8515266	usd
CY2021	GHSI	Cumulative Effect Adjustment CumulativeEffectAdjustment	26265	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	33662596	usd
CY2021	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3568415	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	600887	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	669379	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24745009	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22297800	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8834898	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8783800	usd
CY2022	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1134040	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	941585	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	225564	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	82266	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	9033	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14922228	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14922228	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24745009	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1248789	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	782920	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10065833	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2022	GHSI	Gain Loss On Termination Of Leases GainLossOnTerminationOfLeases	-24257	usd
CY2021	GHSI	Gain Loss On Termination Of Leases GainLossOnTerminationOfLeases	-106477	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-9448	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-160137	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1996	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	20695	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	55609	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	179222	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	124628	usd
CY2022	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	225564	usd
CY2021	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	600887	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	82266	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	669379	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2345800	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	94286	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-378681	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2807339	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-451122	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91946	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	971420	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1276545	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-680697	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-337190	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	768127	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22222	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-233741	usd
CY2021	us-gaap	Increase Decrease In Due To Officers And Stockholders IncreaseDecreaseInDueToOfficersAndStockholders	-148958	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7446812	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10644416	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5569	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74592	usd
CY2022	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills	77591741	usd
CY2021	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills	70952562	usd
CY2022	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills	82587364	usd
CY2021	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills	65956939	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	25941186	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4990054	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31011401	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8834899	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33662597	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4308415	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1134040	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3568415	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9033	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14268321	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37231012	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11811563	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4424805	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4093927	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8518732	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15905490	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4093927	usd
CY2021	GHSI	Adjust Warrant Liability AdjustWarrantLiability	26265	usd
CY2022	GHSI	Issuance Of Warrant Liability IssuanceOfWarrantLiability	8783800	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14922228	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7446812	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10655490	usd
CY2022Q1	GHSI	Minimum Closing Bid Price Value MinimumClosingBidPriceValue	1.00
CY2022Q3	GHSI	Minimum Closing Bid Price Value MinimumClosingBidPriceValue	1.00
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-30
CY2022Q3	GHSI	Minimum Closing Bid Price Value MinimumClosingBidPriceValue	1.00
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100
CY2022	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	Reverse Stock Split became effective, every 50 shares of the Company’s issued and outstanding common stock were automatically combined, converted and changed into 1 share of the Company’s common stock
CY2022	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	On January 24, 2023, Guardion Health Sciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company’s common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	segment
CY2021Q4	GHSI	Winding Description WindingDescription	During the fourth quarter of 2021, the Company announced it would be winding down the Medical Devices Segment, which accounted for approximately 4% of revenue in 2021
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2021Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-6 reverse split
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zT5oki4gEwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span id="xdx_86D_zFv8GBRA8kQ">Use of Estimates</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11049772	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7233118	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11049772	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7233118	usd
CY2022	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	9135351	usd
CY2021	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	3398629	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10655490	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	GHSI	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	67681	usd
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	488539	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5250000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1996	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	20695	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	55609	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	179222	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10065833	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	42990000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1618199	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	161833	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193800	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64358	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	61246	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1540662	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24592	shares
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4995623	usd
CY2022	GHSI	Fair Value Of Warrant Derivative Liability Recognized Upon Issuance Of Warrants FairValueOfWarrantDerivativeLiabilityRecognizedUponIssuanceOfWarrants	8783800	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2345800	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24257	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	25308	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22221	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3807	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-106477	usd
CY2021	GHSI	Percentage Of Writtendown Revenue PercentageOfWrittendownRevenue	0.04	pure
CY2020Q4	GHSI	Derivative Liability DerivativeLiability	25978	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	12765911	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-22171583	usd
CY2021	GHSI	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	-47.00
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	48911	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	148826	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P0Y2M1D
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.039	pure
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	begin to expire in 2035
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	49637	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	53320	usd
CY2022Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	3069784	usd
CY2021Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	314371	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	367691	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	55609	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	179222	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	176131	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	247705	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	127260	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	136327	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48871	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111378	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1267340	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1267340	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488539	shares
CY2022	us-gaap	Depreciation Depreciation	58789	usd
CY2021	us-gaap	Depreciation Depreciation	91575	usd
CY2021Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	9200000	usd
CY2021Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	2700000	usd
CY2021Q4	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	50000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11950000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	694167	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11255833	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1190000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10065833	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10065833	usd
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	11893134	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2021	GHSI	Goodwill Impairment Percentage GoodwillImpairmentPercentage	0.16	pure
CY2021Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11893134	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2200	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3826	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3826	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3807	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3807	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2345800	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The holders of the Preferred Stock have the right to require the Company to redeem their shares of preferred stock for cash at 105% of the stated value of such shares through February 27, 2023 which is 90 days from the issue date of the Preferred Stock. The Company has the option to redeem the Preferred Stock for cash at 105% of the stated value commencing after receipt of stockholder approval of the Reverse Split, subject to the rights of the holders of Series C Preferred Stock to convert their shares of Series C Preferred Stock into common stock prior to such redemption. The Company classifies the Preferred Stock outside of permanent equity (as temporary equity within the mezzanine section between liabilities and equity on the consolidated balance sheets) since the redemption of such shares is not solely within the Company’s contro
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	941585	usd
CY2022Q4	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The Certificates of Designation for the Preferred Stock provides that the Preferred Stock have no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000 votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment to authorize a reverse split of the Common Stock was approved at a special meeting of shareholders. Following the meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares of common stock
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4750000	usd
CY2022	GHSI	Proceeds From Issuance Of Private Placement Additional ProceedsFromIssuanceOfPrivatePlacementAdditional	500000	usd
CY2022	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.05	pure
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1526701	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15564	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	474.00
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M17D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6220	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	135.00
CY2021	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4722	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17062	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	317.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1333	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.50
CY2022	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2014	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3087	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13294	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	217.05
CY2022	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10217	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	252.06
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13294	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10217	shares
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0065	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.070	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.2165	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.280	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2165	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.280	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10594000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8329000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1485000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1637000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	17000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	12000	usd
CY2022Q4	GHSI	Deferred Tax Assets Charitable Contribution DeferredTaxAssetsCharitableContribution	4000	usd
CY2021Q4	GHSI	Deferred Tax Assets Charitable Contribution DeferredTaxAssetsCharitableContribution	3000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	7000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	137000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4949000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	39000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16546000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10126000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	510000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	31000	usd
CY2022Q4	GHSI	Deferred Tax Liabilities Unrealized Gains Losses DeferredTaxLiabilitiesUnrealizedGainsLosses	490000	usd
CY2021Q4	GHSI	Deferred Tax Liabilities Allowance For Doubtful Accounts DeferredTaxLiabilitiesAllowanceForDoubtfulAccounts	4000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	10000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	13000	usd
CY2022Q4	GHSI	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	10000	usd
CY2021Q4	GHSI	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	13000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	510000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	31000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q1	GHSI	Minimum Share Closing Bid Price MinimumShareClosingBidPrice	1.00
CY2022Q1	us-gaap	Assets Assets	31620528	usd
CY2022Q1	GHSI	Warrant Derivative Liabilities WarrantDerivativeLiabilities	11466300	usd
CY2022Q1	us-gaap	Liabilities Liabilities	13292708	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102369452	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84103059	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18327820	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31620528	usd
CY2022Q2	us-gaap	Assets Assets	29834743	usd
CY2022Q2	GHSI	Warrant Derivative Liabilities WarrantDerivativeLiabilities	6108700	usd
CY2022Q2	us-gaap	Liabilities Liabilities	7801894	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102418670	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80447422	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	22032849	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29834743	usd
CY2022Q3	us-gaap	Assets Assets	28228212	usd
CY2022Q3	GHSI	Warrant Derivative Liabilities WarrantDerivativeLiabilities	5235500	usd
CY2022Q3	us-gaap	Liabilities Liabilities	6968726	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102468219	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81270334	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	21259486	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28228212	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2384619	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5004667	usd
CY2022Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-2682500	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2680939	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.00
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3275213	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4986791	usd
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	5357600	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5367215	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	3655637	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.00
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2663550	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4402944	usd
CY2022Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	873200	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	916482	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-822912	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5659832	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8323382	usd
	GHSI	Cost Of Goods Services Sold And Operating Expenses CostOfGoodsServicesSoldAndOperatingExpenses	9991458	usd
	GHSI	Cost Of Goods Services Sold And Operating Expenses CostOfGoodsServicesSoldAndOperatingExpenses	14394402	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2675100	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	3548300	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2686276	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3602758	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1645350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2468262	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.50
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2682500	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2226473	usd
CY2022Q1	GHSI	Issuance Of Warrant Derivative Liability IssuanceOfWarrantDerivativeLiability	8783800	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1645350	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2675100	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4800765	usd
	GHSI	Issuance Of Warrant Derivative Liability IssuanceOfWarrantDerivativeLiability	8783800	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2468262	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3548300	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6082906	usd
	GHSI	Issuance Of Warrant Derivative Liability IssuanceOfWarrantDerivativeLiability	8783800	usd

Files In Submission

Name	View Source	Status
0001493152-23-012449-index-headers.html	Edgar Link	pending
0001493152-23-012449-index.html	Edgar Link	pending
0001493152-23-012449.txt	Edgar Link	pending
0001493152-23-012449-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
ghsi-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
ghsi-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ghsi-20221231_pre.xml	Edgar Link	unprocessable
ghsi-20221231_def.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ghsi-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GHSI
Guardion Health Sciences Inc Stock $ghsi

2023 Q1 Form 10-K Financial Statement

#000149315223012449 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI Guardion Health Sciences Inc Stock $ghsi

2023 Q1 Form 10-K Financial Statement

#000149315223012449 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI
Guardion Health Sciences Inc Stock $ghsi